Skip to main content

Day: March 9, 2021

Emerging Markets Report: A Psychedelic Story

An Emerging Markets Sponsored CommentaryORLANDO, Fla., March 09, 2021 (GLOBE NEWSWIRE) — Last month we introduced our readership to XPhyto Therapeutics Corp. (XPHYF). At such time, we mentioned that the Company is also involved in psychedelics and that we would dive into that matter at a later date.Today’s that date.For the uninitiated, psychedelic companies have been enjoying increased interest in North American stock markets as research portends significant possible clinical use. Take a look at this article from Forbes.Here’s a brief excerpt:“Like cannabis, the psychedelics industry has been growing at a locomotive pace. A key reason is an intriguing trend within the mental health community: the evolving acceptance of psychedelic drugs for treating depression and other mental disorders.XPhyto has a world view, having published...

Continue reading

Gilat Announces Appointment of Isaac Angel as Chairman of the Board

PETAH TIKVA, Israel, March 09, 2021 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announces the appointment of Isaac Angel as Gilat’s Chairman of the Board. Isaac Angel’s appointment is effective immediately, taking over from Dov Baharav who has stepped down and retired after a seven-year tenure.Isaac Angel brings with him a wealth of experience and accomplishments from his current and previous positions. Mr. Angel serves as Chairman of the Board and served as CEO at Ormat Technologies Inc., a global company delivering renewable power and energy solutions. Before his seven-year tenure as an officer and director at Ormat, Mr. Angel held executive positions at LeadCom Integrated Solutions, VeriFone and Lipman Electronic...

Continue reading

LifeMD to Participate at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021

NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) — LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, has been invited to participate at the 33rd Annual ROTH Growth Conference being held virtually on March 15-17, 2021.The conference will feature presentations from public and private companies across a variety of industry sectors, followed by one-on-one and small group meetings, as well as expert panels and fireside chats. Past events have featured more than 550 participating companies and drawn more than 5,000 attendees, including institutional investors, analysts, family offices and high-net-worth investors.LifeMD CEO Justin Schreiber will participate in one-on-one meetings with investors and analysts during the conference. He will be joined by the company’s CFO, Marc Benathen, and chief business officer, Corey...

Continue reading

Nominations Announced for JUNO Fan Choice Presented by Freedom Mobile, with Voting on TikTok

Freedom Mobile signs on as new Lead Sponsor and Official Mobile Partner of The 50th Annual JUNO Awards and TikTok joins as new Lead Sponsor and Official Voting Platform of JUNO Fan ChoiceVoting is now open for JUNO Fan Choice Presented by Freedom Mobile. Fans are encouraged to vote on TikTok and at junofanchoice.caTORONTO, March 09, 2021 (GLOBE NEWSWIRE) — The Canadian Academy of Recording Arts and Sciences (CARAS) is pleased to announce the nominees for JUNO Fan Choice Presented by Freedom Mobile. New this year, Freedom Mobile has signed on as a Lead Sponsor of The 50thAnnual JUNO Awards and the new Presenting Partner of the JUNO Fan Choice Award. TikTok has also joined as a Lead Sponsor and has been named as the Official Voting Platform, where fans can discover and vote their favourite nominee directly in the app.JUNO Fan Choice...

Continue reading

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2020

New Collaboration with Merck Will Evaluate SRF388, Targeting IL-27, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid TumorsCAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation therapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fourth quarter and full year 2020, as well as anticipated 2021 corporate milestones.“The fourth quarter of 2020 was transformational for Surface. During this quarter, we provided encouraging clinical data from our lead candidates and validated our preclinical discovery capabilities with a second major outlicense agreement that provided the company with substantial financial flexibility for several years,” said Rob Ross, M.D.,...

Continue reading

COMPASS Pathways plc announces financial results and business highlights for fourth quarter and year-end 2020

LONDON, March 09, 2021 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and year-end 2020 and gave an update on recent progress across its business.George Goldsmith, Chairman, CEO and Co-founder, COMPASS Pathways, said, “Mental health is an urgent crisis and this has only been exacerbated by the COVID-19 pandemic. At COMPASS we remain committed to transforming mental health care and helping patients who are suffering and aren’t helped by existing treatments. Our phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression is actively recruiting and we plan to report data from this trial at the end of the year. We are also...

Continue reading

Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma

– Treatment of animal osteosarcoma models with dovitinib increased the median survival timeby 50 % as compared to control animals.Press release  Hørsholm, Denmark (9 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced positive data from its preclinical assessment of dovitinib’s antitumor activity in osteosarcoma, the most common primary malignant bone tumor in children and young adults. The purpose of the study was to investigate the capacity of dovitinib alone, and in combination with a specific checkpoint inhibition strategy (anti-PD-1), for slowing the progression of experimental pulmonary metastases in animal models of osteosarcoma. Two separate studies, performed contemporaneously in a syngeneic, mouse model of experimental pulmonary osteosarcoma metastases in mice using the K7M2 cell line,...

Continue reading

XPO Logistics Distribution Center Achieves 23-Year Safety Record

GREENWICH, Conn, March 09, 2021 (GLOBE NEWSWIRE) — XPO Logistics, Inc. (NYSE: XPO), a leading global provider of supply chain solutions, today announced that its logistics site on Industrial Boulevard in Plaquemine, Louisiana has achieved a company-best safety record of 23 years — 8,492 consecutive days without a single recordable incident, as defined by the US Occupational Safety and Health Administration (OSHA). The 300,000-square-foot warehouse manages storage and distribution for a global agribusiness customer.Ashfaque Chowdhury, president, supply chain – Americas and Asia Pacific, XPO Logistics, said, “The Plaquemine site’s outstanding safety record shows what can be achieved when our company’s culture is put into practice daily. I commend the entire team on their uncompromising commitment to operational excellence and, above...

Continue reading

Kamada to Present at the Jefferies Global Plasma Summit

REHOVOT, Israel, March 09, 2021 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived biopharmaceutical company, announced today that Amir London, Chief Executive Officer, will present a corporate overview at the inaugural Jefferies Virtual Global Plasma Summit, being held on March 11, 2021.Mr. London is scheduled to present at 9:35 a.m. Eastern Time. The presentation will be accessible via a live webcast at: https://wsw.com/webcast/jeff171/kmda/1823556. A replay of the presentation will be accessible via the link and will be available for 30 days following the event.About KamadaKamada Ltd. (the “Company”) is a global specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company’s strategy...

Continue reading

Triterras Announces Strategic Partnership with Western Union Business Solutions

SINGAPORE, March 09, 2021 (GLOBE NEWSWIRE) — Triterras Inc. (Nasdaq: TRIT, TRITW) (“Triterras” or the “Company”), a leading fintech company for trade and trade finance, today announced its partnership with Western Union Business Solutions to provide cross-border payments services between traders and lenders on its Kratos platform.Under this partnership, Western Union Business Solutions’ will offer Kratos users access to fast and reliable technology for the movement of global funds, and expertise in currency risk management. As a leading provider of global payments technology Western Union Business Solutions is a strong complement to Triterras and its blockchain-enabled Kratos platform.“This strategic partnership provides us with an opportunity to reduce our client’s transaction cycle times which will further reduce the borrowing...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.